Your session is about to expire
← Back to Search
Monoclonal Antibodies
Mosunetuzumab + Tiragolumab for Lymphoma
Phase 1 & 2
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the time of first study treatment to death from any cause (up to approximately 4 years)
Awards & highlights
Study Summary
This trial will study the safety and efficacy of mosunetuzumab in combination with other drugs to treat people with relapsed or refractory DLBCL or FL.
Who is the study for?
Adults with B-cell non-Hodgkin lymphoma, including diffuse large B-cell and follicular lymphoma, who have tried at least two treatments without success. Participants must be in stable condition with a life expectancy of over 12 weeks and able to undergo certain biopsies. Those eligible can't have other major health issues or recent surgeries, nor can they be candidates for stem cell transplant.Check my eligibility
What is being tested?
The trial is testing the combination of mosunetuzumab with tiragolumab, and in some cases also atezolizumab, to see how safe and effective these drugs are together for treating certain types of B-cell lymphomas that haven't responded well to previous therapies.See study design
What are the potential side effects?
Possible side effects include allergic reactions to monoclonal antibodies like skin rashes or difficulty breathing; organ inflammation; fatigue; blood disorders such as low counts leading to increased infection risk; liver problems; heart complications.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from the time of first study treatment to death from any cause (up to approximately 4 years)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the time of first study treatment to death from any cause (up to approximately 4 years)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Best Objective Response Rate (ORR) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 2)
Percentage of Participants with Adverse Events (Phase 1b)
Secondary outcome measures
Best Complete Response (CR) Rate as Determined by the Investigator Using Lugano 2014 Criteria (Phase 1b and Phase 2)
Best ORR as Determined by the Investigator Using Lugano 2014 Criteria (Phase 1b)
Duration of Response (DOR) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 1b and Phase 2)
+7 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Subcutaneous (SC) Mosunetuzumab in Combination with Intravenous (IV) TiragolumabExperimental Treatment3 Interventions
Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
Group II: Mosunetuzumab SC in Combination with Tiragolumab IV and Atezolizumab IVExperimental Treatment4 Interventions
Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mosunetuzumab SC
2022
Completed Phase 2
~10
Tiragolumab
2020
Completed Phase 2
~350
Atezolizumab
2017
Completed Phase 3
~5860
Find a Location
Who is running the clinical trial?
Hoffmann-La RocheLead Sponsor
2,428 Previous Clinical Trials
1,089,046 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,199 Previous Clinical Trials
888,494 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You currently have or have had cancer in the brain or spinal cord.You have received any of the following treatments before joining the study: mosunetuzumab or other drugs that target CD20/CD3; tiragolumab or other drugs that target TIGIT; allogenic stem cell transplant; or solid organ transplant.You have experienced negative side effects from previous immunotherapy treatments as specified in the study guidelines.You have a specific type of lymphoma (FL or DLBCL) that has come back or has not responded to at least two different treatments. There are no other effective treatment options available for you at this time.You have a condition that makes it unsafe for you to take atezolizumab or tocilizumab.You have serious heart, lung, brain, or liver problems, or currently have an active infection.You are expected to live for at least 12 more weeks.You are able to undergo a bone marrow biopsy and aspirate, which involves collecting a small sample from your bone marrow.You have had severe allergic reactions to certain types of antibody treatments in the past.
Research Study Groups:
This trial has the following groups:- Group 1: Subcutaneous (SC) Mosunetuzumab in Combination with Intravenous (IV) Tiragolumab
- Group 2: Mosunetuzumab SC in Combination with Tiragolumab IV and Atezolizumab IV
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants are included in the research investigation?
"For this trial to be successful, 118 participants that qualify for the included criteria must be recruited. Providing two examples, USC Norris Comprehensive Cancer Center in Los Angeles and University of Michigan at Ann Arbor are both valid locations for patient enrollment."
Answered by AI
Are there any vacant slots available in this experiment for participants?
"As confirmed on clinicaltrials.gov, this research initiative is currently recruiting participants. This trial was initially posted on May 10th 2022 and has since been revised as of November 1st 2022."
Answered by AI
How many locations in this state are currently conducting the research project?
"Amongst other institutions, this clinical trial is being held at USC Norris Comprehensive Cancer Center in Los Angeles, California, University of Michigan in Ann Arbor, Michigan and Tom Baker Cancer Centre-Calgary in Calgary, Alberta."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger